KYMR – Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc.KYMR
$76.91Name : Kymera Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,326,431,232.00
EPSttm : -3.58
Kymera Therapeutics, Inc.
$76.91
4.00%$2.96
KYMR — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
14.03
Margin Of Safety %
Put/Call OI Ratio
2.19
EPS Next Q Diff
-1.16
EPS Last/This Y
0.13
EPS This/Next Y
-0.81
Price
77.08
Target Price
118.55
Analyst Recom
1.12
Performance Q
-9.07
Upside
-160.3%
Beta
2.04
Ticker: KYMR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | KYMR | 84 | 1.44 | 3.33 | 3333 |
| 2026-05-12 | KYMR | 83.62 | 1.42 | 1.14 | 3306 |
| 2026-05-13 | KYMR | 85.66 | 1.43 | 0.00 | 3315 |
| 2026-05-14 | KYMR | 84.52 | 1.42 | 0.40 | 3311 |
| 2026-05-15 | KYMR | 82.26 | 1.42 | 0.89 | 3310 |
| 2026-05-18 | KYMR | 79.77 | 1.90 | 1.11 | 1549 |
| 2026-05-19 | KYMR | 78.24 | 1.81 | 1.14 | 1686 |
| 2026-05-20 | KYMR | 80.63 | 1.90 | 0.02 | 1633 |
| 2026-05-21 | KYMR | 80.56 | 1.78 | 1.00 | 1668 |
| 2026-05-22 | KYMR | 78.86 | 1.79 | 0.10 | 1671 |
| 2026-05-26 | KYMR | 80.78 | 1.80 | 999.99 | 1715 |
| 2026-05-27 | KYMR | 81.75 | 1.87 | 0.06 | 1757 |
| 2026-05-28 | KYMR | 81.5 | 1.77 | 999.99 | 1792 |
| 2026-05-29 | KYMR | 81.38 | 1.98 | 1.00 | 1927 |
| 2026-06-02 | KYMR | 71.35 | 2.01 | 14.29 | 2044 |
| 2026-06-03 | KYMR | 73.3 | 2.14 | 8.00 | 2149 |
| 2026-06-04 | KYMR | 74.67 | 2.16 | 0.00 | 2162 |
| 2026-06-05 | KYMR | 74.24 | 2.15 | 0.00 | 2165 |
| 2026-06-08 | KYMR | 73.99 | 2.15 | 30.00 | 2165 |
| 2026-06-09 | KYMR | 76.93 | 2.19 | 0.00 | 2195 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | KYMR | 84.10 | 24.8 | - | -3.44 |
| 2026-05-12 | KYMR | 83.59 | 24.8 | - | -3.54 |
| 2026-05-13 | KYMR | 85.63 | 24.8 | - | -3.54 |
| 2026-05-14 | KYMR | 84.49 | 20.3 | - | -3.56 |
| 2026-05-15 | KYMR | 82.23 | 20.3 | - | -3.56 |
| 2026-05-18 | KYMR | 79.66 | 20.3 | - | -3.56 |
| 2026-05-19 | KYMR | 78.13 | 20.3 | - | -3.56 |
| 2026-05-20 | KYMR | 80.77 | 20.3 | - | -3.56 |
| 2026-05-21 | KYMR | 80.56 | 20.3 | - | -3.56 |
| 2026-05-22 | KYMR | 78.84 | 20.3 | - | -3.56 |
| 2026-05-26 | KYMR | 80.73 | 20.3 | - | -3.56 |
| 2026-05-27 | KYMR | 81.76 | 20.3 | - | -3.56 |
| 2026-05-28 | KYMR | 81.44 | 20.3 | - | -3.56 |
| 2026-05-29 | KYMR | 81.37 | 20.3 | - | -3.56 |
| 2026-06-01 | KYMR | 78.52 | 20.3 | - | -3.56 |
| 2026-06-02 | KYMR | 71.37 | 20.3 | - | -3.56 |
| 2026-06-03 | KYMR | 73.31 | 20.3 | - | -3.56 |
| 2026-06-04 | KYMR | 74.57 | 20.3 | - | -3.56 |
| 2026-06-05 | KYMR | 74.12 | 20.3 | - | -3.56 |
| 2026-06-08 | KYMR | 73.96 | 20.3 | - | -3.56 |
| 2026-06-09 | KYMR | 77.08 | 20.3 | - | -3.56 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | KYMR | 11.42 | 7.58 | 13.58 |
| 2026-05-12 | KYMR | 11.39 | 7.58 | 13.67 |
| 2026-05-13 | KYMR | 11.39 | 7.58 | 13.67 |
| 2026-05-14 | KYMR | 11.39 | 7.58 | 13.67 |
| 2026-05-15 | KYMR | 11.39 | 7.58 | 13.67 |
| 2026-05-18 | KYMR | 11.39 | 7.34 | 13.65 |
| 2026-05-19 | KYMR | 11.50 | 7.34 | 13.65 |
| 2026-05-20 | KYMR | 11.50 | 7.34 | 13.65 |
| 2026-05-21 | KYMR | 11.50 | 7.34 | 13.62 |
| 2026-05-22 | KYMR | 11.67 | 7.34 | 13.62 |
| 2026-05-26 | KYMR | 11.67 | 8.81 | 13.62 |
| 2026-05-27 | KYMR | 11.65 | 8.81 | 13.62 |
| 2026-05-28 | KYMR | 11.46 | 8.81 | 14.07 |
| 2026-05-29 | KYMR | 11.46 | 8.81 | 14.07 |
| 2026-06-02 | KYMR | 11.48 | 8.09 | 14.06 |
| 2026-06-03 | KYMR | 11.48 | 8.09 | 14.06 |
| 2026-06-04 | KYMR | 11.48 | 8.09 | 14.06 |
| 2026-06-05 | KYMR | 11.48 | 8.09 | 14.03 |
| 2026-06-08 | KYMR | 11.68 | 8.03 | 14.03 |
| 2026-06-09 | KYMR | 13.44 | 8.03 | 14.03 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.13
Avg. EPS Est. Current Quarter
-0.76
Avg. EPS Est. Next Quarter
-1.03
Insider Transactions
13.44
Institutional Transactions
8.03
Beta
2.04
Average Sales Estimate Current Quarter
29
Average Sales Estimate Next Quarter
8
Fair Value
Quality Score
30
Growth Score
25
Sentiment Score
45
Actual DrawDown %
25.2
Max Drawdown 5-Year %
-83.5
Target Price
118.55
P/E
Forward P/E
PEG
P/S
122.89
P/B
4.11
P/Free Cash Flow
EPS
-3.57
Average EPS Est. Cur. Y
-3.56
EPS Next Y. (Est.)
-4.37
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-611.96
Relative Volume
1.33
Return on Equity vs Sector %
-47.9
Return on Equity vs Industry %
-31.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.09
EBIT Estimation
◆
KYMR
Healthcare
$76.91
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
44.7
Range 1M
33.2%
Sup Dist
5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
5.8%
EPS NY
-23.8%
52W%
59.5%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+54.1% upside
Upside
+54.1%
Quality
30
Kymera Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 253
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
KYMR
Latest News
—
Caricamento notizie per KYMR…
stock quote shares KYMR – Kymera Therapeutics, Inc. Stock Price stock today
news today KYMR – Kymera Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KYMR – Kymera Therapeutics, Inc. yahoo finance google finance
stock history KYMR – Kymera Therapeutics, Inc. invest stock market
stock prices KYMR premarket after hours
ticker KYMR fair value insiders trading